BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26490944)

  • 1. Quantitative Proteomics Analysis of Vitreous Humor from Diabetic Retinopathy Patients.
    Loukovaara S; Nurkkala H; Tamene F; Gucciardo E; Liu X; Repo P; Lehti K; Varjosalo M
    J Proteome Res; 2015 Dec; 14(12):5131-43. PubMed ID: 26490944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New exploration of treatment target for proliferative diabetic retinopathy based on iTRAQ LC-MS/MS Proteomics].
    Wen DJ; Ren XJ; Dong LJ; He Y; Li XR
    Zhonghua Yan Ke Za Zhi; 2019 Oct; 55(10):769-776. PubMed ID: 31607066
    [No Abstract]   [Full Text] [Related]  

  • 3. A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.
    Cehofski LJ; Honoré B; Vorum H
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28452939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
    Aiello LP; Avery RL; Arrigg PG; Keyt BA; Jampel HD; Shah ST; Pasquale LR; Thieme H; Iwamoto MA; Park JE
    N Engl J Med; 1994 Dec; 331(22):1480-7. PubMed ID: 7526212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
    Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
    Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Proteomic Landscape in the Vitreous of Patients With Age-Related and Diabetic Retinal Disease.
    Schori C; Trachsel C; Grossmann J; Zygoula I; Barthelmes D; Grimm C
    Invest Ophthalmol Vis Sci; 2018 Mar; 59(4):AMD31-AMD40. PubMed ID: 30025106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy.
    Gao BB; Chen X; Timothy N; Aiello LP; Feener EP
    J Proteome Res; 2008 Jun; 7(6):2516-25. PubMed ID: 18433156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients.
    Kim T; Kim SJ; Kim K; Kang UB; Lee C; Park KS; Yu HG; Kim Y
    Proteomics; 2007 Nov; 7(22):4203-15. PubMed ID: 17955474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy.
    Yokoi M; Yamagishi SI; Takeuchi M; Ohgami K; Okamoto T; Saito W; Muramatsu M; Imaizumi T; Ohno S
    Br J Ophthalmol; 2005 Jun; 89(6):673-5. PubMed ID: 15923499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. System-wide vitreous proteome dissection reveals impaired sheddase activity in diabetic retinopathy.
    Alli-Shaik A; Qiu B; Lai SL; Cheung N; Tan G; Neo SP; Tan A; Cheung CMG; Hong W; Wong TY; Wang X; Gunaratne J
    Theranostics; 2022; 12(15):6682-6704. PubMed ID: 36185601
    [No Abstract]   [Full Text] [Related]  

  • 13. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone.
    Brooks HL; Caballero S; Newell CK; Steinmetz RL; Watson D; Segal MS; Harrison JK; Scott EW; Grant MB
    Arch Ophthalmol; 2004 Dec; 122(12):1801-7. PubMed ID: 15596583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy.
    Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F
    Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.
    Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA
    Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy.
    Marek N; Raczyńska K; Siebert J; Myśliwiec M; Zorena K; Myśliwska J; Reiwer-Gostomska M; Trzonkowski P
    Microvasc Res; 2011 Jul; 82(1):1-5. PubMed ID: 21539846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
    Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
    Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
    Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
    Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.
    Dyer KH; Silva PS; Sun JK
    Semin Ophthalmol; 2013; 28(5-6):347-54. PubMed ID: 24138044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy.
    Semeraro F; Cancarini A; Morescalchi F; Romano MR; dell'Omo R; Ruggeri G; Agnifili L; Costagliola C
    Diabetes Metab; 2014 Dec; 40(6):445-51. PubMed ID: 24878492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.